Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
Retrieved on:
Thursday, February 24, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Canadian Society for Clinical Investigation, Plant, Clinical, GlaxoSmithKline, Vaccine, Severe acute respiratory syndrome coronavirus 2, Health, Marketing, Mitsubishi Tanabe Pharma, VLP, COVID-19, Virus-like particle, Antigen, Government of Canada, GSK, The Honourable, Health Canada, Infection, Technology, Solution, Research, Vaccination, Government, CEO, CoVLP, Interim order, Pharmaceutical industry, Medicago, Industry, Science
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
Key Points:
- Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
- The approval of our COVID-19 vaccine is a significant milestone for Canada in the fight against the pandemic.
- We look forward to working with Medicago to make the vaccine available in Canada and to progress further regulatory submissions.
- The Government of Canada has a contract with Medicago (the Marketing Authorization Holder) to supply the COVID-19 vaccine.